To evaluate the suitability of sacubitril valsartan prescriptions to the recommendations in a health management area.

**Objective**

To evaluate the suitability of sacubitril valsartan prescriptions to the recommendations in a health management area.

**Materials and methods**

Retrospective descriptive study including patients treated with sacubitril valsartan from September 2016 until July 2017.

**Background**

In Spain, therapeutic positioning report (TPR) for sacubitril valsartan indicates its use.

In adult patients for symptomatic chronic heart failure and:

- Reduced ejection fraction (LVEF < 35%)
- Elevated B-type natriuretic peptid (BNP) seric levels
- Well previously treated with standard of care therapy

**VARIABLES**

- Sex, age, treatment with ACE inhibitors, beta-blockers, mineralcorticoid antagonists and/or diuretics, dosage regimen, contraindications or intolerance to standard therapy, LVEF, dose escalation, dose reduction, discontinuation and cause of discontinuation.

To evaluate the suitability of the prescriptions we analysed: intolerance/contraindications to standard therapy, therapy before change, dosage regimen, dose tritation and LEVF ≤ 35%.

- Audit data were sent to their prescriptors to review.
- To data compilation we used the Microstrategy® prescription database and medical records.

**Results**

53 patients. Median age 66.6 years. 83% (n=44) men.

- 11.3% (n=6) optimal dose
- 9.4% (n=5) optimal dose
- 0.5% (n=3) optimal dose

- No intolerance or contraindication to standard therapy
- Correct dose tritation/appropriate periodic exam: 16 patients (30%).
- 1 dose reduction for hypotension and 10 discontinuations: 4 lack of indication, 2 hypotension, 1 exitus, 1 cardiac transplantation and 1 economic conditions.

**Conclusions**

- The results show an inadequate use of sacubitril valsartan according to TPR indications in most cases.
- With this analysis we intend to improve sacubitril valsartan use in our reference area.
- Audit are an effective method to improve rational use of medicines.